事项:1)三生制药在2025 年STIC 会议上公布707 联合化疗治疗1L NSCLC 的临床2 期研究数据。2)辉瑞电话会讨论707 全球临床策略。国信医药观点:1)近日,三生制药在STIC 会议上公布707 联合化疗治疗1L NSCLC 的临床2 期研究数据,数据显示707 联合化疗在sqNSCLC 和nsqNSCLC 中均具备良好的有效性和安全性,支持707 联合化疗继续在1L NSCLC...
Source Link事项:1)三生制药在2025 年STIC 会议上公布707 联合化疗治疗1L NSCLC 的临床2 期研究数据。2)辉瑞电话会讨论707 全球临床策略。国信医药观点:1)近日,三生制药在STIC 会议上公布707 联合化疗治疗1L NSCLC 的临床2 期研究数据,数据显示707 联合化疗在sqNSCLC 和nsqNSCLC 中均具备良好的有效性和安全性,支持707 联合化疗继续在1L NSCLC...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.